Literature DB >> 30153995

Strategies to maximize influenza vaccine impact in older adults.

Jennifer A Whitaker1, Mitchell S von Itzstein2, Gregory A Poland3.   

Abstract

Older adults are disproportionately affected by influenza morbidity and mortality. In most high income countries, influenza vaccine policies target persons age ≥65 years for influenza vaccination. Many low-resource settings do not utilize seasonal influenza vaccination. Barriers to influenza prevention among older adults around the globe are multiple and some vary between high- and low-resource settings. To maximize influenza prevention in the older adult population, gaps in influenza vaccination coverage and improvements in vaccine efficacy are needed. The focus of this article is on the data for currently available vaccine strategies to maximize influenza vaccine impact, with a focus on high-resource settings. We also discuss novel influenza vaccine strategies needed for older adults worldwide.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvants; Adult; Aged; Immunocompromised host; Immunologic; Influenza vaccines; Influenza, Human; Vaccination

Mesh:

Substances:

Year:  2018        PMID: 30153995     DOI: 10.1016/j.vaccine.2018.08.040

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Peripheral follicular helper T cells in acute viral diseases: a perspective on dengue.

Authors:  Luis A Sánchez-Vargas; Anuja Mathew
Journal:  Future Virol       Date:  2019-03-06       Impact factor: 1.831

Review 2.  Respiratory viral infections in the elderly.

Authors:  Alastair Watson; Tom M A Wilkinson
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

Review 3.  Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion.

Authors:  T Mark Doherty; Giuseppe Del Giudice; Stefania Maggi
Journal:  Ann Med       Date:  2019-04-26       Impact factor: 4.709

4.  Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.

Authors:  Angus H Forster; Katey Witham; Alexandra C I Depelsenaire; Margaret Veitch; James W Wells; Adam Wheatley; Melinda Pryor; Jason D Lickliter; Barbara Francis; Steve Rockman; Jesse Bodle; Peter Treasure; Julian Hickling; Germain J P Fernando
Journal:  PLoS Med       Date:  2020-03-17       Impact factor: 11.069

5.  Influenza Vaccine Effectiveness Estimates among US Department of Defense Adult Beneficiaries over Four Consecutive Influenza Seasons: A Test-Negative Design Study with Different Control Groups.

Authors:  Wenping Hu; Paul A Sjoberg; Laurie S DeMarcus; Anthony S Robbins
Journal:  Vaccines (Basel)       Date:  2021-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.